Protalix BioTherapeutics, Inc. Share Price & Technical Analysis
PLX · $2.10 (+3.45%)
Healthcare / Biotechnology
$2.10
+3.45%
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also de…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-5% return in May, -28% avg return in past 3 year May month.
28% return in 2026, 32% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 28% | 26% | -21% | 0% | -5% | – | – | – | – | – | – | – | 28% |
| 25 | 26% | -4% | 13% | 19% | -52% | 0% | 0% | 7% | 38% | 9% | -25% | 0% | 32% |
| 24 | -17% | 7% | -24% | -8% | -8% | 9% | -8% | -18% | 0% | 20% | 42% | 12% | 6% |
| 23 | 14% | 27% | 5% | 33% | -25% | -5% | -20% | 19% | -11% | 6% | -6% | 20% | 58% |
| 22 | 0% | -11% | 22% | 9% | 9% | -8% | 0% | 0% | -9% | 0% | 10% | 27% | 49% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$153.70M
P/E ratio
—
52W high
$3.19
52W low
$1.32
Volume
6,80,778
Beta
-0.01
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Protalix BioTherapeutics, Inc. share price today?
- Protalix BioTherapeutics, Inc. (PLX) last traded around $2.10 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PLX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PLX. Download the app for real-time alerts.
- How can I analyze Protalix BioTherapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.